RECURRENT MYCOSIS FUNGOIDES
Clinical trials for RECURRENT MYCOSIS FUNGOIDES explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MYCOSIS FUNGOIDES trials appear
Sign up with your email to follow new studies for RECURRENT MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug targets Hard-to-Treat lymphoma in early trial
Disease control OngoingThis early-phase trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have returned or not improved after standard treatments. The drug is a monoclonal antibody designed to help the immune system fight cancer. The main goals are to find the …
Matched conditions: RECURRENT MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:34 UTC
-
Experimental combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a drug called durvalumab, given alone or with lenalidomide, in people with T-cell lymphoma that returned or didn't respond to prior treatments. The goal is to find the best dose and see how well the combination works. About 38 adults with certain types of T-cell …
Matched conditions: RECURRENT MYCOSIS FUNGOIDES
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New combo therapy offers hope for patients with relapsed T-Cell lymphoma
Disease control OngoingThis study tests a combination of two drugs, pembrolizumab (an immunotherapy that helps the immune system attack cancer) and romidepsin (a drug that blocks enzymes cancer cells need to grow), in people with peripheral T-cell lymphoma that has come back or stopped responding to tr…
Matched conditions: RECURRENT MYCOSIS FUNGOIDES
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC